68Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients

被引：6

作者：

Sanli, Yasemin ^{[1
]}

Sanli, Oner ^{[3
]}

Simsek, Duygu Has ^{[4
]}

Subramaniam, Rathan M. ^{[1
,2
]}

机构：

[1] Univ Texas Southwestern Med Ctr Dallas, Dept Radiol, Div Nucl Med, Dallas, TX USA

[2] Univ Texas Southwestern Med Ctr Dallas, Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA

[3] Istanbul Univ, Istanbul Fac Med, Dept Urol, Istanbul, Turkey

[4] Istanbul Univ, Istanbul Fac Med, Dept Nucl Med, Istanbul, Turkey

来源：

NUCLEAR MEDICINE COMMUNICATIONS | 2018年 / 39卷 / 10期

关键词：

Ga-68-PET; MRI; Ga-68-PSMA PET; CT; high-risk prostate cancer; MEMBRANE ANTIGEN-EXPRESSION; POSITRON-EMISSION-TOMOGRAPHY; ESTRO-SIOG GUIDELINES; RADICAL PROSTATECTOMY; DIAGNOSTIC-ACCURACY; EXTRACAPSULAR EXTENSION; DISEASE RECURRENCE; LYMPH-NODES; WHOLE-BODY; THERAPY;

D O I：

10.1097/MNM.0000000000000888

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Treatment of high-risk prostate cancer (HRPCa) is challenging. Local staging and metastatic evaluation are important for the patient management. Recently, prostate-specific membrane antigen (PSMA)-based imaging modalities such as PSMA PET/CT and PET/MRI have received significant attention for detection of recurrent prostate cancer sites with elevated prostate-specific antigen levels, after therapy. Current evidence suggests that these imaging modalities may also have a role for the management of patients with HRPCa. In this review, we discuss PSMA-based imaging modalities in the management of patients with HRPCa.

引用

页码：871 / 880

页数：10

共 50 条

[31] The Utility of 68Ga-PSMA PET/CT in Poorly Differentiated Metastatic Prostate Cancer
Demirkol, Mehmet Onur
Kiremit, Murat Can
Acar, Omer
Ucar, Burcu
Saglican, Yesim
CLINICAL NUCLEAR MEDICINE, 2017, 42 (05) : 403 - 405
[32] Imaging of Prostate Cancer Recurrence in the Vas Deferens With 68Ga-PSMA PET/CT
Priftakis, Dimitrios
Afaq, Asim
Bomanji, Jamshed
CLINICAL NUCLEAR MEDICINE, 2020, 45 (01) : 49 - 51
[33] Distinguishing Meningioma From Metastasis of Prostate Cancer on 68Ga-PSMA PET/CT
Filizoglu, Nuh
Oksuzoglu, Kevser
Ozguven, Salih
CLINICAL NUCLEAR MEDICINE, 2021, 46 (11) : E553 - E555
[34] 68Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature
Zacho, Helle D.
Nielsen, Julie B.
Haberkorn, Uwe
Stenholt, Louise
Petersen, Lars J.
CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING, 2018, 38 (06) : 911 - 922
[35] MRI versus 68Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer
Zamboglou, Constantinos
Wieser, Gesche
Hennies, Steffen
Rempel, Irene
Kirste, Simon
Soschynski, Martin
Rischke, Hans Christian
Fechter, Tobias
Jilg, Cordula A.
Langer, Mathias
Meyer, Philipp T.
Bock, Michael
Grosu, Anca-Ligia
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (05) : 889 - 897
[36] Performance of 68Ga-PSMA PET/CT for Prostate Cancer Management at Initial Staging and Time of Biochemical Recurrence
Bailey, Jason
Piert, Morand
CURRENT UROLOGY REPORTS, 2017, 18 (11)
[37] Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer
Chuanchi Zhou
Yongxiang Tang
Zhihe Deng
Jinhui Yang
Ming Zhou
Long Wang
Shuo Hu
EJNMMI Research, 12
[38] 68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report
Isabel Rauscher
Tobias Maurer
Wolfgang P. Fendler
Wieland H. Sommer
Markus Schwaiger
Matthias Eiber
Cancer Imaging, 16
[39] 68Ga-PSMA PET/CT in prostate cancer patients - patterns of disease, benign findings and pitfalls
Keidar, Zohar
Gill, Ronit
Goshen, Elinor
Israel, Ora
Davidson, Tima
Morgulis, Maryna
Pirmisashvili, Natalia
Ben-Haim, Simona
CANCER IMAGING, 2018, 18
[40] Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by 68Ga-PSMA PET/CT
Christensen, Mads T.
Jochumsen, Mads R.
Klingenberg, Soren
Sorensen, Karina D.
Borre, Michael
Bouchelouche, Kirsten
DIAGNOSTICS, 2022, 12 (01)

← 1 2 3 4 5 →